"Warfarin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
| Descriptor ID |
D014859
|
| MeSH Number(s) |
D03.383.663.283.446.520.914 D03.633.100.150.446.520.914
|
| Concept/Terms |
Warfarin- Warfarin
- 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
|
Below are MeSH descriptors whose meaning is more general than "Warfarin".
Below are MeSH descriptors whose meaning is more specific than "Warfarin".
This graph shows the total number of publications written about "Warfarin" by people in this website by year, and whether "Warfarin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2011 | 2 | 1 | 3 |
| 2013 | 2 | 1 | 3 |
| 2014 | 2 | 0 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 3 | 3 | 6 |
| 2017 | 49 | 23 | 72 |
| 2018 | 47 | 24 | 71 |
| 2019 | 15 | 8 | 23 |
| 2020 | 3 | 1 | 4 |
| 2021 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Warfarin" by people in Profiles.
-
Evaluation of the "safe multidisciplinary app-assisted remote patient-self-testing (SMART) model" for warfarin home management during the COVID-19 pandemic: study protocol of a multi-center randomized controlled trial. BMC Health Serv Res. 2021 Aug 26; 21(1):875.
-
The short-term effect of the COVID-19 pandemic on the management of warfarin therapy. Kardiologiia. 2021 Jul 31; 61(7):55-59.
-
Warfarin anticoagulation in the Covid-19 pandemic: Telephone-based management at a regional hematology outpatient center in Joinville, Brazil. Thromb Res. 2021 09; 205:81-83.
-
Side-Effects of COVID-19 on Patient Care: An INR Story. J Appl Lab Med. 2021 07 07; 6(4):953-961.
-
Anti-PF4 antibody negative cerebral venous sinus thrombosis without thrombocytopenia following immunization with COVID-19 vaccine in an elderly non-comorbid Indian male, managed with conventional heparin-warfarin based anticoagulation. Diabetes Metab Syndr. 2021 Jul-Aug; 15(4):102184.
-
An unexpected case of recurrence of pulmonary embolism in a patient recovered from COVID19 in full regimen dose of direct oral anticoagulant drug. BMC Pulm Med. 2021 Mar 24; 21(1):102.
-
Gene variants of coagulation related proteins that interact with SARS-CoV-2. PLoS Comput Biol. 2021 03; 17(3):e1008805.
-
Outpatient management of chronic warfarin therapy at a pharmacist-run anticoagulation clinic during the COVID-19 pandemic. J Thromb Thrombolysis. 2021 Oct; 52(3):754-758.
-
Embracing Genetic Diversity to Improve Black Health. N Engl J Med. 2021 Mar 25; 384(12):1163-1167.
-
Anticoagulation clinic drive-up service during COVID-19 pandemic in Qatar. J Thromb Thrombolysis. 2021 Feb; 51(2):297-300.